Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) received a Form 144 notice indicating that officer Robert Andrade plans to sell 75,000 shares of Fennec common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC – Executive Financial Services, with an indicated aggregate market value of $883,897.50 and trading on NASDAQ.

The shares to be sold were acquired directly from the issuer upon the exercise of stock options for cash during the period from 08/13/2020 through 03/26/2026. A notice date of 08/27/2026 is reported, and no prior three‑month sales are listed in the disclosure.

Key Figures

Shares to be sold: 75,000 shares of Common Stock Aggregate market value: $883,897.50 Rule 144 holding/acquisition period: 08/13/2020 through 03/26/2026 +2 more

5 metrics

Shares to be sold 75,000 shares of Common Stock Amount of FENNEC PHARMACEUTICALS INC. common shares covered by the Form 144 notice

Aggregate market value $883,897.50 Aggregate market value reported for the 75,000 common shares to be sold

Rule 144 holding/acquisition period 08/13/2020 through 03/26/2026 Period during which the shares were acquired upon exercise of stock options

Date of Notice 08/27/2026 Date associated with the Form 144 notice filed for the proposed sale

Security type Common Stock Class of FENNEC PHARMACEUTICALS INC. securities to be sold under the notice

Key Terms

Rule 144, Form 144, Stock Options, aggregate market value, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Form 144 regulatory

"144: Filer Information 144: Issuer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Options financial

"acquired upon the exercise of Stock Options during the period of 08/13/2020"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... 883897.50"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Person for Whose Account the Securities are To Be Sold regulatory

"Name of Person for Whose Account the Securities are To Be Sold | ROBERT ANDRADE"

FAQ

What does the Form 144 filing disclose for FENC?

It discloses that Robert Andrade, an officer of FENNEC PHARMACEUTICALS INC. (FENC), has filed a notice of intent to sell 75,000 shares of Fennec common stock under Rule 144 through Morgan Stanley Smith Barney LLC on NASDAQ.

How many FENC shares are planned to be sold under this Form 144?

The filing reports a planned sale of 75,000 shares of FENNEC PHARMACEUTICALS INC. common stock. These shares were acquired upon the exercise of stock options and are the total amount listed in the securities information section.

What is the aggregate market value of the FENC shares covered by this Form 144?

The Form 144 lists an aggregate market value of approximately $883,897.50 for the 75,000 FENNEC PHARMACEUTICALS INC. shares to be sold, based on the price information provided in the securities section.

How and when were the FENC shares in this Form 144 acquired?

The filing states that the securities to be sold were acquired upon the exercise of Stock Options from the issuer for cash during the period from 08/13/2020 through 03/26/2026.

Who is the broker for the planned FENC share sale?

The broker identified is Morgan Stanley Smith Barney LLC – Executive Financial Services, located at 1 New York Plaza, New York. The Form 144 links this broker to the planned sale of 75,000 Fennec common shares on NASDAQ.

What is the notice date on this Form 144 for FENC?

The Form 144 shows a Date of Notice of 08/27/2026. This is the date associated with the filing of the notice covering the proposed sale of 75,000 FENNEC PHARMACEUTICALS INC. common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:21 PM Accepted by SEC EDGAR 08/27/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001468308
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	FENNEC PHARMACEUTICALS INC.
SEC File Number	001-32295
Address of Issuer	PO BOX 13628, 68 TW ALEXANDER DRIVE Research Triangle Park NORTH CAROLINA 27709
Phone	(919) 636-4530
Name of Person for Whose Account the Securities are To Be Sold	ROBERT ANDRADE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75000	883897.50	35067159	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2020	Exercised Shares	ISSUER			75000	08/13/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the exercise of Stock Options during the period of 08/13/2020 through 03/26/2026.
Date of Notice	08/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Andrade
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)